ALS
48 programs · 46 companies
Programs
48
Companies
46
Trials
41
MOAs
33
AHRantFXIaiCD47iKRASG12DiAnti-AβBETiCAR-T CD19JAK1/2iSGLT2iWRNi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | Phase 2/3 | GIP-R | ||
| BMY-9931 | Phase 1 | GPRC5D | ||
| BGN-3859 | Approved | PSMA | ||
| DAW-5540 | Phase 2 | AHR | ||
| TNG-8610 | NDA/BLA | GIP-R | ||
| 187-151 | Phase 1 | Aβ | ||
| MAY-IIT-516 | Phase 3 | AHR | ||
| AFF-3518 | Phase 1 | HER2 | ||
| VIG-1206 | Phase 3 | CFTR | ||
| Datofutibatinib | Approved | GLP-1R | ||
| Daranesiran | Phase 2/3 | CGRP | ||
| Adagranaritide | Phase 2 | CD20 | ||
| XBI-3618 | Phase 1 | GIP-R | ||
| Tiracilimab | Phase 1 | PLK4 | ||
| Elrafotisoran | Phase 3 | FLT3 | ||
| KTO-5045 | Approved | PCSK9 | ||
| 601-209 | Phase 2/3 | TYK2 | ||
| 195-4808 | Preclinical | TIM-3 | ||
| BIO-9035 | Phase 2/3 | MDM2 | ||
| BIO-6952 | NDA/BLA | KRASG12D | ||
| Liraratamab | Approved | FcRn | ||
| MED-3086 | Preclinical | CFTR | ||
| Niramavacamten | Preclinical | Cl18.2 | ||
| ABB-879 | Phase 1 | WEE1 | ||
| Mirituximab | Phase 2 | FcRn | ||
| OCT-7288 | Phase 2/3 | CD123 | ||
| IMM-5834 | Phase 2 | FGFR | ||
| PBL-1430 | Phase 1/2 | CD19 | ||
| DUK-IIT-769 | Approved | BCL-2 | ||
| Semasertib | Phase 2 | HER2 | ||
| NTR-8128 | Phase 3 | Nectin-4 | ||
| Kemarelsin | NDA/BLA | WEE1 | ||
| 4D-3071 | Approved | BCMA | ||
| Terafotisoran | Phase 1/2 | PI3Kα | ||
| GNF-1172 | NDA/BLA | PRMT5 | ||
| MRK-6740 | Phase 2/3 | B7-H3 | ||
| Capitenlimab | Phase 1 | VEGF | ||
| Darasotorasib | Preclinical | PCSK9 | ||
| Capirapivir | Approved | VEGF | ||
| Sovafutibatinib | Phase 1/2 | SHP2 | ||
| BCA-6126 | Phase 2/3 | MALT1 | ||
| Lisofotisoran | NDA/BLA | FcRn | ||
| Daranesiran | Preclinical | IL-23 | ||
| CAM-IIT-192 | Phase 2 | AHR | ||
| RUI-IIT-706 | NDA/BLA | CGRP | ||
| AII-IIT-782 | Phase 2/3 | EZH2 | ||
| ELA-3520 | Phase 2 | CD19 | ||
| Datozumab | Phase 1/2 | PCSK9 |
Trials (41)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08229550 | AZN-5978 | Phase 2/3 | Active |
| NCT03557585 | AZN-5978 | Phase 2/3 | Not yet recr... |
| NCT07950561 | BMY-9931 | Phase 1 | Recruiting |
| NCT07249712 | DAW-5540 | Phase 2 | Completed |
| NCT03453479 | TNG-8610 | NDA/BLA | Not yet recr... |
| NCT03238978 | MAY-IIT-516 | Phase 3 | Completed |
| NCT06453885 | Daranesiran | Phase 2/3 | Completed |
| NCT07960590 | Elrafotisoran | Phase 3 | Completed |
| NCT03055018 | Elrafotisoran | Phase 3 | Active |
| NCT08287302 | KTO-5045 | Approved | Recruiting |
| NCT07233155 | 195-4808 | Preclinical | Terminated |
| NCT06089063 | BIO-9035 | Phase 2/3 | Terminated |
| NCT04170207 | BIO-6952 | NDA/BLA | Recruiting |
| NCT07629821 | Niramavacamten | Preclinical | Recruiting |
| NCT04306763 | ABB-879 | Phase 1 | Terminated |
| NCT08629000 | Mirituximab | Phase 2 | Not yet recr... |
| NCT03850365 | OCT-7288 | Phase 2/3 | Recruiting |
| NCT08249629 | IMM-5834 | Phase 2 | Terminated |
| NCT08079750 | IMM-5834 | Phase 2 | Terminated |
| NCT08445847 | DUK-IIT-769 | Approved | Not yet recr... |